Soon-Shiong Companies Green-Lighted to Move Cancer Vaccine Into Clinic

May 12, 2017

By Michael Fitzhugh, Staff Writer
Nantcell and Nantkwest Inc. have gained FDA permission to start enrolling a phase Ib/II trial of the Nant cancer vaccine, a step toward what Nantkwest CEO Patrick Soon-Shiong has said is a quest to develop a vaccine intended to induce immunogenic cell death and orchestrate patients’ innate and adaptive immune systems.

Contact us at


How Can ImmunityBio Help You?

Solutions for Patients

Many therapies for treating cancer and infectious diseases severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

Natural killer cell-based immunotherapies are key to future cancer treatments. Our investigational NK-92®-engineered cells have demonstrated wide therapeutic potential across multiple tumor types, and, in clinical studies, have proven to be well-tolerated, making them ideal for clinical trial investigations.

Solutions for Research Scientists

Our NK-92® cell line provides a versatile bioanalytical testing solution that helps researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it.